ChinaFocus@Boston | Premier Biotech and Healthcare Events

June 4, 2023

Hilton Boston/Woburn

2 Forbes Road, Woburn, MA 01801, United States

Apply to Present

general registration

INVESTOR REGISTRATION

Countdown Timer

Day(s)

Hour(s)

Minute(s)

Second(s)

ABOUT CHINA FOCUS

China has embraced a vigorously growing healthcare market in the past decade. Ever since joining ICH in 2017, China has seen increased clinical trials and accelerated new drug and device approval. For biotech and medtech companies outside of China, you need to find the right partners and the right resources to bring your products to China, in order to adapt to difference in culture, regulation, reimbursement, etc. In the meantime, Chinese biotechs are actively seeking global market entry opportunities and oversea partners.

China Focus is a partnering forum designed to provide a meaningful platform to inform, inspire, and foster cross-border partnership in life science and healthcare.

Who should attend

Investors (VC, PE, investment bank, etc.)
Life science innovators and entrepreneurs
Biotech & big pharma
Medtech (device and diagnostics) manufacturers and distributors
Service providers (law firm, financial advisory, regulatory consulting, CRO, CDMO, etc.)
Healthcare providers

Main Topics

Cross-border investment: money from the East and the West
Innovations going to China: regulation, market access, manufacturing and distribution
Chinese innovations going west: partnership for capital and market access in the U.S.

What you can get

Learn about Chinese life science and healthcare industry
Hear about the latest Chinese regulatory reforms and implications
Meet with the decision makers in the industry
Initiate business conversations that otherwise difficult to start

REGISTRATION

Agenda

08:00-09:00●

Check in

09:00-09:10●

Opening Remarks

Larry Cai, Venture Partner of MybioCapital

09:10-09:30●

Keynote: Capturing innovative and market opportunities in China

Helen Chen, Global Sector Co-Head for Healthcare&Greater China Managing Partner, L.E.K

BD&Investment and Financing Sub-venue

09:30-10:10 ●

Panel: Discussion on International Cooperation Opportunities for China's Original Research and Innovative Drugs

Moderator: Larry Cai, Venture Partner of MybioCapital
Guests:
Jenny Yang, Head of external innovation Asia Pacific，Novo Nordisk
John Lu, President and CEO, HebeCell
Brian Yang, VP&Head of Corporate Strategy and BD, ArkBio
Leo Bao, Venture Partner of MybioCapital
Bin Chen, Vice President of MedChem, XtalPi

10:10-10:50 ●

Panel: China Pharmaceutical BD International Cooperation Successful Experience Sharing

Moderator: Sara Chen,　VP of Business Development, NeoLogics
Guests: Weihao Xu, CFO&CBO, Harbour BioMed
Joan Shen, Founder&CEO, NeuShen Therapeutics
Ben Zhao, Founder&President, Haichang Biotech
Ping Cao, Chief Business Officer/VP of Business Development, Henlius
Kelvin Shao, VP of Business Development, Kexing Biopharma

10:50-11:00●

Do's and Don't's in cross border BD collaborations

Wendy Pan, Partner, GOODWIN

11:10-11:40 ●

Real world case experience sharing

Moderator: Wendy Pan, Partner, GOODWIN
Guests: Larry Cai, Venture Partner of MybioCapital
Seamus Jiang – U.S./China Cross-border Deals Leader Managing Director, PwC US

11:40-13:30 ●

Lunch Break

Enmore Biologics Development Summit ( Organizer: Enmore Healthcare & Wuxi Biologics )

13:30-14:00●

Interpretation of Product Access Policy in the US Market

Wesely, CEO, CUBIO

14:00-14:30●

Accelerated CMC development from DNA to IND

Sherry Gu, WuxiBiologics US&EU CMC Management SVP

14:30-15:00●

An Intergraded Overview on High Concentration Drug Product Development and manufacturing-from FormulationtoAutoinjectorse

Jeremy Guo, Wuxi Biologics, Drug product development and DP manufacturing VP

15:00-15:30●

Industrialization of Chemically Defined(CD) Media: Development, Production Strategies, and Case Study Analysis

Yantao Wang Shanghai Maibang (Medium Bank) Biotechnology Chairman and CEO

15:30-16:30●

Panel: Discussion on the futureR&D and CMC trend of biopharmaceuticals

Moderator: Jijie Gu, Wuxi Biologics CSO
Guests: Sherry Gu, Wuxi Biologics US& EU CMC Management SVP
Wei Gan, Zenas Bio SVP
Stacy Price, Chief Technology&Manufacturing Officer, Invivyd

16:30-17:00●

Fourth revolutionary wave of Biologics Manufacturing

Peng Jiao，CEO of BiBo Biopharma Engineering Co.,Ltd.

17:00-17:30●

M4: A novel therapeutic oligonucleotide solution to obesity-induced disease and muscle wasting

Luke Chen, Founder&CEO, xNA Biotechnology

17:30-18:30●

Cocktail Party